470.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$458.49
Aprire:
$461.03
Volume 24 ore:
1.00M
Relative Volume:
0.66
Capitalizzazione di mercato:
$120.73B
Reddito:
$11.10B
Utile/perdita netta:
$-988.90M
Rapporto P/E:
-119.93
EPS:
-3.92
Flusso di cassa netto:
$-1.26B
1 W Prestazione:
+1.28%
1M Prestazione:
+6.64%
6M Prestazione:
+9.84%
1 anno Prestazione:
-5.20%
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2024-12-20 | Reiterato | H.C. Wainwright | Buy |
2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
2024-11-14 | Iniziato | Citigroup | Buy |
2024-10-16 | Iniziato | Scotiabank | Sector Perform |
2024-10-10 | Ripresa | Raymond James | Mkt Perform |
2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
2024-06-27 | Iniziato | Redburn Atlantic | Buy |
2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
2024-02-15 | Iniziato | Wolfe Research | Outperform |
2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
2023-05-30 | Iniziato | William Blair | Outperform |
2023-05-04 | Ripresa | Piper Sandler | Overweight |
2023-03-21 | Iniziato | Bernstein | Outperform |
2023-01-18 | Iniziato | Canaccord Genuity | Hold |
2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2022-12-19 | Downgrade | Jefferies | Buy → Hold |
2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2022-01-27 | Reiterato | JP Morgan | Overweight |
2022-01-27 | Reiterato | Morgan Stanley | Underweight |
2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
2022-01-27 | Reiterato | Stifel | Hold |
2022-01-27 | Reiterato | Wolfe Research | Outperform |
2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
2021-12-09 | Iniziato | Wells Fargo | Overweight |
2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
2021-09-09 | Downgrade | Stifel | Buy → Hold |
2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
2021-07-19 | Ripresa | Wolfe Research | Outperform |
2021-07-01 | Iniziato | Raymond James | Mkt Perform |
2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2021-02-02 | Reiterato | H.C. Wainwright | Buy |
2020-12-30 | Iniziato | Daiwa Securities | Outperform |
2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2020-11-20 | Iniziato | Bernstein | Outperform |
2020-10-28 | Iniziato | UBS | Buy |
2020-07-31 | Reiterato | H.C. Wainwright | Buy |
2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-04-30 | Reiterato | H.C. Wainwright | Buy |
2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2020-03-04 | Iniziato | Barclays | Overweight |
2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
2019-11-12 | Iniziato | SunTrust | Buy |
2019-10-17 | Ripresa | BofA/Merrill | Buy |
2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
2019-08-01 | Downgrade | Needham | Buy → Hold |
2019-05-23 | Ripresa | Citigroup | Buy |
2019-05-21 | Iniziato | Credit Suisse | Outperform |
2019-04-12 | Iniziato | Evercore ISI | In-line |
2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Nasdaq
Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies - The Globe and Mail
What analysts say about Vertex Pharmaceuticals Incorporated stockFree Stock Chart Pattern Guide - Autocar Professional
Vertex Pharmaceuticals: Pioneering Orphan Drug Innovation in Cystic Fibrosis and Cementing Market Leadership - AInvest
Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis - The Malaysian Reserve
Is Vertex Pharmaceuticals Incorporated a good long term investmentTriple-digit wealth increases - jammulinksnews.com
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
What drives Vertex Pharmaceuticals Incorporated stock priceConsistent triple returns - jammulinksnews.com
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need To Know - Barchart.com
Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga
Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest
Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative
Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharmaceuticals: Strong Growth Driven by Cystic Fibrosis Success and Strategic Expansions - TipRanks
Vertex Pharmaceuticals Surges to 213th in Trading Volume with $460 Million in Shares Traded Despite Stock Price Decline - AInvest
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment - Yahoo Finance
England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek - insights.citeline.com
Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug - BioPharma Dive
Peripheral Neuropathic Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Trevena, Afasci, Lexicon Pharma, Haisco Pharma, Vertex Pharma - Barchart.com
EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment - Insider Monkey
Vertex secures NHS deal for once-daily cystic fibrosis therapy - The Pharma Letter
Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value - Yahoo Finance
Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE - PMLiVE
NICE backs Vertex's cystic fibrosis triple combo Alyftrek - FirstWord Pharma
Vertex Pharmaceuticals (VRTX) Receives a Buy from J.P. Morgan - The Globe and Mail
New cystic fibrosis triple from Vertex backed for NHS use - pharmaphorum
Vertex Pharmaceuticals and NHS England Reach Agreement to Provide Alyftrek for Cystic Fibrosis Treatment - geneonline.com
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain - BioSpace
Vertex Pharmaceuticals' ALYFTREK® Approval: A Catalyst for EU Dominance and Revenue Growth? - AInvest
(Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX - Business Wire
Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Yahoo Finance
Vertex Pharmaceuticals: A Steady Hand in a Volatile Market - AInvest
Vertex Pharmaceuticals Leads Biotech Stocks with 16%+ YTD Increase - AInvest
Why Vertex Pharmaceuticals Continues To Outperfrom (NASDAQ:VRTX) - Seeking Alpha
Small Fiber Neuropathy Market Growth Projections 2023-2032: DelveInsight Analysis | Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharma, Helixmith, Lexicon Pharma, Glenmark Pharma, Regency - Barchart.com
Regulatory tracker: Vertex, NHS England reach reimbursement deal for CF drug Alyftrek - Fierce Pharma
Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch (NASDAQ:VRTX) - Seeking Alpha
Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval - PMLiVE
Vertex Pharmaceuticals Q2 2025 Earnings: A Catalyst for Dominance in Rare Disease Therapeutics - AInvest
Vertex to Announce Second Quarter 2025 Financial Results on August 4th - Business Wire
Cystic Fibrosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma - Barchart.com
RBC Capital Remains a Hold on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)? - Insider Monkey
FDA Approves Suzetrigine by Vertex Pharmaceuticals for Acute Pain Relief in Adults - geneonline.com
Vertex Pharmaceuticals to Announce Q2 2025 Earnings on August 4th - AInvest
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):